New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareThymagen vs ARA-290

Thymagen vs ARA-290

Side-by-side comparison of key properties, dosing, and research.

Immune Support
Thymagen
Immune SupportRecovery & Repair
ARA-290
Summary
Thymagen is a dipeptide bioregulator (Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for the thymus gland. It supports T-lymphocyte maturation, thymic function, and immune system normalization. As the thymus involutes with age (thymic atrophy), immune competence declines. Thymagen is used to support immune restoration, particularly in aging, post-illness recovery, and immunodeficiency states.
ARA-290 is a synthetic 11-amino acid peptide derived from the helix B region of erythropoietin (EPO). Unlike EPO, it selectively activates the innate repair receptor (IRR) without stimulating hematopoiesis, providing tissue protection, anti-inflammation, and neuropathy relief.
Half-Life
Short (minutes); sustained gene-regulatory effects
~2–4 hours (SC administration)
Admin Route
SubQ, Oral
SubQ
Research
Typical Dose
10 mg per day
4 mg (fixed dose)
Frequency
Daily for 10–30 days
Once daily
Key Benefits
  • Supports thymic epithelial cell function and T-cell maturation
  • May partially restore thymic output reduced by age-related atrophy
  • Normalizes T-lymphocyte subpopulation balance
  • Supports immune recovery after illness, surgery, or chemotherapy
  • Anti-aging effects on thymic tissue
  • Complementary to Thymosin Alpha-1 and Thymalin in immune protocols
  • May improve vaccine responsiveness in older individuals
  • Reduces neuropathic pain from small fiber neuropathy
  • Anti-inflammatory without immune suppression
  • Tissue protection after ischemia/reperfusion injury
  • Promotes nerve fiber regeneration
  • Improves symptoms of sarcoidosis-associated neuropathy
  • May reduce insulin resistance and improve metabolic health
  • Shown to improve autonomic neuropathy symptoms
Side Effects
  • Generally well tolerated
  • Mild injection site reactions
  • No significant immunological adverse events reported
  • Injection site reactions
  • Mild fatigue at initiation
  • Transient warm sensation post-injection
  • Rare: mild headache
Stacks With